The stock of Myovant Sciences Ltd. (NYSE:MYOV) is a huge mover today! The stock increased 12.65% or $1.9 during the last trading session, reaching $16.92. About 3.79 million shares traded or 90.22% up from the average. Myovant Sciences Ltd. (NYSE:MYOV) has declined 63.47% since November 27, 2018 and is downtrending. It has underperformed by 63.47% the S&P500.
The move comes after 6 months positive chart setup for the $1.52B company. It was reported on Nov, 27 by Barchart.com. We have $18.44 PT which if reached, will make NYSE:MYOV worth $136.44M more.
Analysts await Myovant Sciences Ltd. (NYSE:MYOV) to report earnings on February, 6. They expect $-0.79 EPS, up 24.04 % or $0.25 from last year’s $-1.04 per share. After $-0.79 actual EPS reported by Myovant Sciences Ltd. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.
Myovant Sciences Ltd. (NYSE:MYOV) Ratings Coverage
Among 3 analysts covering Myovant Sciences Ltd. Common Shares (NYSE:MYOV), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Myovant Sciences Ltd. Common Shares has $2600 highest and $2000 lowest target. $23.67’s average target is 39.89% above currents $16.92 stock price. Myovant Sciences Ltd. Common Shares had 4 analyst reports since May 30, 2019 according to SRatingsIntel. The stock of Myovant Sciences Ltd. (NYSE:MYOV) has “Buy” rating given on Thursday, May 30 by Citigroup.
More notable recent Myovant Sciences Ltd. (NYSE:MYOV) news were published by: Seekingalpha.com which released: “CRISPR Therapeutics among healthcare gainers; Plus Therapeutics leads the losers – Seeking Alpha” on November 19, 2019, also Benzinga.com with their article: “33 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” published on November 27, 2019, Benzinga.com published: “36 Healthcare Stocks Moving In Monday’s Pre-Market Session – Benzinga” on November 25, 2019. More interesting news about Myovant Sciences Ltd. (NYSE:MYOV) were released by: Benzinga.com and their article: “AstraZeneca CEO: Closing In On A Cancer Cure – Benzinga” published on November 22, 2019 as well as Benzinga.com‘s news article titled: “33 Stocks Moving in Wednesday’s Pre-Market Session – Benzinga” with publication date: November 20, 2019.
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company has market cap of $1.52 billion. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.